Alexandre Corthay

  • Associate Professor, group leader; PhD
  • +47 23 07 41 09

Office: RH A3.3018

 

Publications 2024

Gilmour BC, Corthay A, Øynebråten I (2024)
High production of IL-12 by human dendritic cells stimulated with combinations of pattern-recognition receptor agonists
NPJ Vaccines, 9 (1), 83
DOI 10.1038/s41541-024-00869-1, PubMed 38702320

Wold CW, Christopoulos PF, Arias MA, Dzovor DE, Øynebråten I, Corthay A, Inngjerdingen KT (2024)
Fungal polysaccharides from Inonotus obliquus are agonists for Toll-like receptors and induce macrophage anti-cancer activity
Commun Biol, 7 (1), 222
DOI 10.1038/s42003-024-05853-y, PubMed 38396285

Publications 2023

Anderson CC, Bonney EA, Mueller TF, Corthay A, Havele C, Singh NJ, Øynebråten I, Bretscher PA (2023)
On antigen-specific signals, immune class regulation and energetics: Report III from the workshops on foundational concepts of immune regulation
Scand J Immunol, 98 (3), e13311
DOI 10.1111/sji.13311, PubMed 38112131

Publications 2022

Corthay A, Höglund P (2022)
Immunology according to Dembic: Preserving integrity is key
Scand J Immunol, 95 (5), e13173
DOI 10.1111/sji.13173, PubMed 35474516

Eek Mariampillai A, Hauge S, Øynebråten I, Rødland GE, Corthay A, Syljuåsen RG (2022)
Caspase activation counteracts interferon signaling after G2 checkpoint abrogation by ATR inhibition in irradiated human cancer cells
Front Oncol, 12, 981332
DOI 10.3389/fonc.2022.981332, PubMed 36387237

Publications 2021

Bretscher P, Corthay A, Dembic Z, Rammensee HG (2021)
Obituary: Dr Zoltan A. Nagy (1941-2020)
Scand. J. Immunol., 93 (5), e13027
DOI 10.1111/sji.13027

Christopoulos PF, Grigalavicius M, Corthay A, Berg K, Theodossiou TA (2021)
Reactive Species from Two-Signal Activated Macrophages Interfere with Their Oxygen Consumption Measurements
Antioxidants (Basel), 10 (7)
DOI 10.3390/antiox10071149, PubMed 34356382

Corthay A, Bakacs T, Thangavelu G, Anderson CC (2021)
Tackling cancer cell dormancy: Insights from immune models, and transplantation
Semin Cancer Biol, 78, 5-16
DOI 10.1016/j.semcancer.2021.02.002, PubMed 33582171

Frafjord A, Buer L, Hammarström C, Aamodt H, Woldbæk PR, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2021)
The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
Front Immunol, 12, 764596
DOI 10.3389/fimmu.2021.764596, PubMed 34868011

Publications 2020

Frafjord A, Skarshaug R, Hammarström C, Stankovic B, Dorg LT, Aamodt H, Woldbaek PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A (2020)
Antibody combinations for optimized staining of macrophages in human lung tumours
Scand J Immunol, 92 (1), e12889
DOI 10.1111/sji.12889, PubMed 32299134

Stankovic B, Aamodt H, Bjørhovde HAK, Müller E, Hammarström C, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2020)
The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases
Scand J Immunol, 92 (2), e12893
DOI 10.1111/sji.12893, PubMed 32433774

Waaler J, Mygland L, Tveita A, Strand MF, Solberg NT, Olsen PA, Aizenshtadt A, Fauskanger M, Lund K, Brinch SA, Lycke M, Dybing E, Nygaard V, Bøe SL, Heintz KM, Hovig E, Hammarström C, Corthay A, Krauss S (2020)
Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models
Commun Biol, 3 (1), 196
DOI 10.1038/s42003-020-0916-2, PubMed 32332858

Publications 2019

Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A (2019)
Immune Cell Composition in Human Non-small Cell Lung Cancer
Front Immunol, 9, 3101
DOI 10.3389/fimmu.2018.03101, PubMed 30774636

Publications 2018

Haabeth OAW, Fauskanger M, Manzke M, Lundin KU, Corthay A, Bogen B, Tveita AA (2018)
CD4+ T-cell-Mediated Rejection of MHC Class II-Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs
Cancer Res, 78 (16), 4573-4585
DOI 10.1158/0008-5472.CAN-17-2426, PubMed 29752262

Müller E, Speth M, Christopoulos PF, Lunde A, Avdagic A, Øynebråten I, Corthay A (2018)
Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation
Front Immunol, 9, 2520
DOI 10.3389/fimmu.2018.02520, PubMed 30450098

Publications 2017

Anderson CC, Bretscher P, Corthay A, Dembic Z, Havele C, Nagy ZA, Øynebråten I (2017)
Immunological Tolerance. Part I of a Report of a Workshop on Foundational Concepts of Immune Regulation
Scand J Immunol, 85 (2), 84-94
DOI 10.1111/sji.12500, PubMed 27885703

Bretscher PA, Corthay A, Anderson CC, Dembic Z, Havele C, Nagy ZA, Øynebråten I (2017)
Immune Class Regulation and Its Medical Significance Part II of a Report of a Workshop on Foundational Concepts of Immune Regulation
Scand J Immunol, 85 (4), 242-250
DOI 10.1111/sji.12525, PubMed 28236642

Christopoulos PF, Corthay A, Koutsilieris M (2017)
Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics
Cancer Treat Rev, 63, 79-95
DOI 10.1016/j.ctrv.2017.11.010, PubMed 29253837

Kurena B, Müller E, Christopoulos PF, Johnsen IB, Stankovic B, Øynebråten I, Corthay A, Zajakina A (2017)
Generation and Functional In Vitro Analysis of Semliki Forest Virus Vectors Encoding TNF-α and IFN-γ
Front Immunol, 8, 1667
DOI 10.3389/fimmu.2017.01667, PubMed 29276511

Müller E, Christopoulos PF, Halder S, Lunde A, Beraki K, Speth M, Øynebråten I, Corthay A (2017)
Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages
Front Immunol, 8, 1383
DOI 10.3389/fimmu.2017.01383, PubMed 29123526

Obando DFG, Frafjord A, Oynebraten I, Corthay A, Olivo-Marin JC, Meas-Yedid V (2017)
MULTI-STAINING REGISTRATION OF LARGE HISTOLOGY IMAGES
2017 IEEE 14TH INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI 2017), 345-348

Speth MT, Repnik U, Müller E, Spanier J, Kalinke U, Corthay A, Griffiths G (2017)
Poly(I:C)-Encapsulating Nanoparticles Enhance Innate Immune Responses to the Tuberculosis Vaccine Bacille Calmette-Guérin (BCG) via Synergistic Activation of Innate Immune Receptors
Mol Pharm, 14 (11), 4098-4112
DOI 10.1021/acs.molpharmaceut.7b00795, PubMed 28974092

Wold CW, Kjeldsen C, Corthay A, Rise F, Christensen BE, Duus JØ, Inngjerdingen KT (2017)
Structural characterization of bioactive heteropolysaccharides from the medicinal fungus Inonotus obliquus (Chaga)
Carbohydr Polym, 185, 27-40
DOI 10.1016/j.carbpol.2017.12.041, PubMed 29421057

Publications 2016

Andersen AN, Landsverk OJ, Simonsen A, Bogen B, Corthay A, Øynebråten I (2016)
Coupling of HIV-1 Antigen to the Selective Autophagy Receptor SQSTM1/p62 Promotes T-Cell-Mediated Immunity
Front Immunol, 7, 167
DOI 10.3389/fimmu.2016.00167, PubMed 27242780

Joly-Battaglini A, Hammarström C, Stankovic B, Aamodt H, Stjärne J, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2016)
Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
F1000Res, 5, 38
DOI 10.12688/f1000research.7599.1, PubMed 27081474

Lorvik KB, Hammarström C, Fauskanger M, Haabeth OA, Zangani M, Haraldsen G, Bogen B, Corthay A (2016)
Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an In Situ Inflammatory Immune Response
Cancer Res, 76 (23), 6864-6876
DOI 10.1158/0008-5472.CAN-16-1219, PubMed 27634753

Publications 2015

Haabeth OA, Lorvik KB, Yagita H, Bogen B, Corthay A (2015)
Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells
Oncoimmunology, 5 (1), e1039763
DOI 10.1080/2162402X.2015.1039763, PubMed 26942052

Publications 2014

Corthay A (2014)
Does the immune system naturally protect against cancer?
Front Immunol, 5, 197
DOI 10.3389/fimmu.2014.00197, PubMed 24860567

Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen B (2014)
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
Front Immunol, 5, 174
DOI 10.3389/fimmu.2014.00174, PubMed 24782871

Publications 2013

Lorvik KB, Haabeth OA, Clancy T, Bogen B, Corthay A (2013)
Molecular profiling of tumor-specific TH1 cells activated in vivo
Oncoimmunology, 2 (5), e24383
DOI 10.4161/onci.24383, PubMed 23762808

Publications 2012

Berge T, Grønningsæter IH, Lorvik KB, Abrahamsen G, Granum S, Sundvold-Gjerstad V, Corthay A, Bogen B, Spurkland A (2012)
SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice
PLoS One, 7 (10), e48239
DOI 10.1371/journal.pone.0048239, PubMed 23144743

Haabeth OA, Bogen B, Corthay A (2012)
A model for cancer-suppressive inflammation
Oncoimmunology, 1 (7), 1146-1155
DOI 10.4161/onci.21542, PubMed 23170261

Lorvik KB, Bogen B, Corthay A (2012)
Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice
Blood, 119 (9), 2176-7
DOI 10.1182/blood-2011-10-388892, PubMed 22383793

Publications 2011

Corthay A, Lorvik KB, Bogen B (2011)
Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer
Scand J Immunol, 73 (6), 527-30
DOI 10.1111/j.1365-3083.2011.02558.x, PubMed 21388431

Haabeth OA, Lorvik KB, Hammarström C, Donaldson IM, Haraldsen G, Bogen B, Corthay A (2011)
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
Nat Commun, 2, 240
DOI 10.1038/ncomms1239, PubMed 21407206

Publications 2009

Corthay A (2009)
How do regulatory T cells work?
Scand J Immunol, 70 (4), 326-36
DOI 10.1111/j.1365-3083.2009.02308.x, PubMed 19751267

Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B (2009)
Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells
Cancer Res, 69 (14), 5901-7
DOI 10.1158/0008-5472.CAN-08-4816, PubMed 19567679

Publications 2008

Funderud A, Aas-Hanssen K, Aksaas AK, Hafte TT, Corthay A, Munthe LA, Orstavik S, Skålhegg BS (2008)
Isoform-specific regulation of immune cell reactivity by the catalytic subunit of protein kinase A (PKA)
Cell Signal, 21 (2), 274-81
DOI 10.1016/j.cellsig.2008.10.013, PubMed 19000925

Publications 2007

Corthay A (2007)
CD4+ T cells cooperate with macrophages for specific elimination of MHC class II-negative cancer cells
Adv Exp Med Biol, 590, 195-208
DOI 10.1007/978-0-387-34814-8_14, PubMed 17191387

Publications 2006

Bogen B, Ruffini PA, Corthay A, Fredriksen AB, Frøyland M, Lundin K, Røsjø E, Thompson K, Massaia M (2006)
Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research
Haematologica, 91 (7), 941-8
PubMed 16818282

Corthay A (2006)
A three-cell model for activation of naïve T helper cells
Scand J Immunol, 64 (2), 93-6
DOI 10.1111/j.1365-3083.2006.01782.x, PubMed 16867153

Publications 2005

Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B (2005)
Primary antitumor immune response mediated by CD4+ T cells
Immunity, 22 (3), 371-83
DOI 10.1016/j.immuni.2005.02.003, PubMed 15780993

Munthe LA, Corthay A, Os A, Zangani M, Bogen B (2005)
Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells
J Immunol, 175 (4), 2391-400
DOI 10.4049/jimmunol.175.4.2391, PubMed 16081810

Publications 2004

Corthay A, Lundin KU, Munthe LA, Frøyland M, Gedde-Dahl T, Dembic Z, Bogen B (2004)
Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models
Cancer Immunol Immunother, 53 (9), 759-69
DOI 10.1007/s00262-004-0504-1, PubMed 15088126

Tjelle TE, Corthay A, Lunde E, Sandlie I, Michaelsen TE, Mathiesen I, Bogen B (2004)
Monoclonal antibodies produced by muscle after plasmid injection and electroporation
Mol Ther, 9 (3), 328-36
DOI 10.1016/j.ymthe.2003.12.007, PubMed 15006599

Publications 2003

Lundin KU, Hofgaard PO, Omholt H, Munthe LA, Corthay A, Bogen B (2003)
Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies
Blood, 102 (2), 605-12
DOI 10.1182/blood-2002-11-3381, PubMed 12649166

Mölne L, Corthay A, Holmdahl R, Tarkowski A (2003)
Role of gamma/delta T cell receptor-expressing lymphocytes in cutaneous infection caused by Staphylococcus aureus
Clin Exp Immunol, 132 (2), 209-15
DOI 10.1046/j.1365-2249.2003.02151.x, PubMed 12699407

Publications 2001

Corthay A, Bäcklund J, Holmdahl R (2001)
Role of glycopeptide-specific T cells in collagen-induced arthritis: an example how post-translational modification of proteins may be involved in autoimmune disease
Ann Med, 33 (7), 456-65
DOI 10.3109/07853890109002094, PubMed 11680793

Corthay A, Nandakumar KS, Holmdahl R (2001)
Evaluation of the percentage of peripheral T cells with two different T cell receptor alpha-chains and of their potential role in autoimmunity
J Autoimmun, 16 (4), 423-9
DOI 10.1006/jaut.2001.0504, PubMed 11437490

Publications 2000

Corthay A (2000)
T cells in autoimmunity: studies on murine type II collagen-induced arthritis
Lund university, Lund, 1 b. (flere pag.)
BIBSYS 001433148, ISBN 91-628-4037-1

Corthay A, Hansson AS, Holmdahl R (2000)
T lymphocytes are not required for the spontaneous development of entheseal ossification leading to marginal ankylosis in the DBA/1 mouse
Arthritis Rheum, 43 (4), 844-51
DOI 10.1002/1529-0131(200004)43:4<844::AID-ANR15>3.0.CO;2-B, PubMed 10765929

Publications 1999

Corthay A, Johansson A, Vestberg M, Holmdahl R (1999)
Collagen-induced arthritis development requires alpha beta T cells but not gamma delta T cells: studies with T cell-deficient (TCR mutant) mice
Int Immunol, 11 (7), 1065-73
DOI 10.1093/intimm/11.7.1065, PubMed 10383939

Publications 1998

Corthay A, Bäcklund J, Broddefalk J, Michaëlsson E, Goldschmidt TJ, Kihlberg J, Holmdahl R (1998)
Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis
Eur J Immunol, 28 (8), 2580-90
DOI 10.1002/(SICI)1521-4141(199808)28:08<2580::AID-IMMU2580>3.0.CO;2-X, PubMed 9710235